COVID-19: A systemic disease treated with a wide-ranging approach: A case report

Authors

  • Rosanna Massabeti Emergency Department, Lugo City Hospital, Ravenna, Italy.
  • Maria Stella Cipriani Emergency Department, Lugo City Hospital, Ravenna, Italy.
  • Ivana Valenti Emergency Department, Lugo City Hospital, Ravenna, Italy.

DOI:

https://doi.org/10.15586/jptcp.v27iSP1.691

Keywords:

coronavirus disease, COVID-19, treatment, monoclonal antibodies,, non-invasive mechanical ventilation

Abstract

At the end of December 2019, the Health Commission of the city of Wuhan, China, alerted the World Health Organization (WHO) to a pneumonia cluster in the city. The cause was identified as being a new virus, later named SARS-CoV-2. We can distinguish three clinical phases of the disease with a distinct pathogenesis, manifestations and prognosis. Here, we describe the case of a 45-year-old male, successfully treated for Coronavirus disease (COVID-19). The patient was feeling sick in early April 2020; he had a fever and pharyngodynia. When he came to our COVID hospital, his breathing was normal. The nasopharyngeal swab specimen turned out positive. High-resolution computed tomography (HRCT) showed mild interstitial pneumonia. The patient was admitted to our department and treated with hydroxychloroquine, ritonavir, darunavir, azithromycin and enoxaparin. On day seven of the disease, the patient’s respiratory condition got worse as he was developing acute respiratory distress syndrome (ARDS). He was given tocilizumab and corticosteroids and was immediately treated with non-invasive mechanical ventilation (NIMV). His condition improved, and in the ensuing days, the treatment gradually switched to a high-flow nasal cannula (HFNC); after 18 days, the patient’s clinical condition was good.
The successful results we have been able to obtain are closely associated with avoidance of invasive ventilation that may lead to intensive care unit (ICU)-related superinfections. In our opinion, it is fundamental to understand that COVID-19 is a systemic disease that is a consequence of an overwhelming inflammatory response, which can cause severe medical conditions, even in young patients.

References

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lancet Respir Med. 2020 Apr;8(4):420–22. https://doi.org/10.1016/S2213-2600(20)30076-X

Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: Old tricks for new challenges. Crit Care. 2020 Mar 16;24(1):91. https://doi. org/10.1186/s13054-020-2818-6

McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;102537. https://doi.org/10.1016/j.autrev. 2020.102537

Wilcox SR. Management of respiratory failure due to covid-19. BMJ. 2020 May 4;369:1786. https://doi.org/10.1136/bmj.m1786

Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020 Mar 29;55(5): 105954. https://doi.org/10.1016/j.ijantimicag.2020. 105954

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020 May 1;35(6490): 473–4. https://doi.org/10.1126/science.abb8925

De Luna G, Habibi A, Deux JF, et al. Rapid and severe covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020 Apr 13;95:876–8. https://doi.org/10.1002/ajh.25833

Buonaguro FM, Puzanov I, Ascierto PA.Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 2020 Apr 14;18(1):165. https://doi.org/10.1186/s12967-020-02333-9

Aziz M, Fatima R, Assaly R. Elevated Interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol. 2020 Apr 28:1–3. https:// doi.org/10.1002/jmv.25948

Liu B, Li M, Zhou Z. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020 Apr 10;111:102452. https://doi.org/10.1016/j.jaut.2020.102452

Cellina M, Orsi M, Bombaci F, et al. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging. 2020 May; 101(5):323–324. https://doi.org/10.1016/j.diii. 2020.03.010

Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: What’s next? Br J Pharmacol. 2020 Apr 24:1–12. https://doi.org/10.1111/bph.15072

Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: A cautionary case report. Chest. 2020 Apr 25. https://doi.org/10.1016/j.chest.2020.04.024 in press

Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: A case report. Ann Oncol. 2020 Apr 2;31(7):961–4 https://doi.org/10.1016/j.annonc.2020.03.300

Lazzeri M, Lanza A, Bellini R. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: A Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Dis. 2020 Mar 26;90(1):163–8. https://doi.org/10.4081/monaldi. 2020.1285

AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020 Apr 2;83:106455. https://doi.org/10.1016/j.intimp.2020. 106455

Fu B, Xu X, Wei H. et al. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020 Apr 14;18(1):164. https://doi. org/10.1186/s12967-020-02339-3

El Ghoch M, Valerio A. Let food be the medicine, but no not for coronavirus. Nutrition and food science telling myths from facts. J Popul Ther Clin Pharmaco. 2020;27(SP1): e1–e4. https://doi.org/10.15586/jptcp.v27iSP1.682

Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 Apr 6;92:814–18. https://doi.org/10.1002/jmv. 25801

Cao X. COVID-19: Immunopathology and its implications for therapy. Nat Rev Immunol. 2020 May;20(5):269–70. https://doi.org/10.1038/ s41577-020-0308-3

Valentini M, Zmerly H. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept. J Popul Ther Clin Pharmaco. 2020;27(SP1):e14-e25. https://doi.org/10.15586/jptcp.v27iSP1.689

Kumar GV, Jeyanthi V, Ramakrishnan S. A short review on antibody therapy for COVID-19. New Microbes New Infect. 2020 Apr 20:100682. https://doi.org/10.1016/j.nmni.2020.100682

Zhang S, Li L, Shen A, Chen Y, et al. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig. 2020 Apr 26;40: 511–18. https://doi.org/10.1007/s40261-020-00917-3

Published

2020-07-03

How to Cite

Massabeti, R., Cipriani , M. S., & Valenti, I. (2020). COVID-19: A systemic disease treated with a wide-ranging approach: A case report. Journal of Population Therapeutics and Clinical Pharmacology, 27(SP1), e26-e30. https://doi.org/10.15586/jptcp.v27iSP1.691
More Citation Formats

How to Cite

Massabeti, R., Cipriani , M. S., & Valenti, I. (2020). COVID-19: A systemic disease treated with a wide-ranging approach: A case report. Journal of Population Therapeutics and Clinical Pharmacology, 27(SP1), e26-e30. https://doi.org/10.15586/jptcp.v27iSP1.691